Vanda Pharmaceuticals Inc (VNDA) FinancialsVNDAVanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Fanapt, accounting for 57.2% of total sales, equivalent to $29.56M. Other significant revenue streams include Hetlioz and PONVORY. Understanding this composition is critical for investors evaluating how VNDA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Vanda Pharmaceuticals Inc maintains a gross margin of 94.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -33.69%, while the net margin is -32.32%. These profitability ratios, combined with a Return on Equity (ROE) of -82.55%, provide a clear picture of how effectively VNDA converts its operational activities into shareholder value.

In the context of the broader market, VNDA competes directly with industry leaders such as ACIU and ELDN. With a market capitalization of $232.51M, it holds a leading position in the sector. When comparing efficiency, VNDA's gross margin of 94.05% stands against ACIU's 100.00% and ELDN's N/A. Such benchmarking helps identify whether Vanda Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Vanda's recent financial performance shows a gross margin of 94.05% in Q3 2026, indicating strong profitability on sales, but the company has faced significant net losses, with a net income of -22,562,000 USD in the same quarter. Additionally, Hetlioz's sales have dropped 66% year-over-year, reflecting challenges in revenue generation.